{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.39","upperLimit":"12.16","value":"7.85"},{"groupId":"OG001","lowerLimit":"1.87","upperLimit":"5.26","value":"3.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"description":"TWP was derived using the worst pain score from brief pain inventory (BPI) and patient reported opioid analgesic use. BPI uses 0 to 10 numeric rating scales asking subjects to rate their pain. TWP results are presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Vandetanib (300 mg daily)","id":"OG000","title":"Vandetanib 300 mg"},{"description":"Placebo daily","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"During the last week of the screening period (Day -7 to Day 0), the brief pain inventory (BPI) and opioid analgesic use were self-reported once a day for 4 days to establish baseline, then every week during blinded study treatment, up to discontinuation.","title":"Time to Worsening of Pain (TWP)","type":"SECONDARY","unitOfMeasure":"Months"}